Forbes August 21, 2024
The recent FDA approval of Eli Lilly’s new immunotherapy for slowing the cognitive decline of early Alzheimer’s marked another step forward in the push to develop effective therapies for this notoriously difficult disease.
After two decades of no new Alzheimer’s drugs, the FDA has approved both this new drug, donanemab, and another immunotherapy called lecanemab in the past couple of years, offering the first glimmers of hope to the more than six million Americans who live with the disease. (In Europe, where I live, that number is estimated to be nearly eight million people.)
Both therapies attempt to clear toxic amyloid proteins from the brain through injectable monoclonal antibodies that are administered via regular infusions. Lecanemab is the most intensive,...
Today's Sponsors
Today's Sponsor